MTTI Obtains FDA Allowance of Investigational New Drug (IND) for Hürthle Cell Thyroid Cancer
WEST CHESTER, PA — Molecular Targeting Technologies, Inc. (MTTI) announced the allowance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). It is now …
MTTI Obtains FDA Allowance of Investigational New Drug (IND) for Hürthle Cell Thyroid Cancer Read More